Perfuze
PrivateLast Round
Series A
Extension
Mar 13, 2025
Total Funding Raised
$76.39M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Perfuze operates in Healthcare & Life Sciences and is based in Ireland. Its latest recorded funding round was a Series A Extension round in March 2025.
Perfuze is a medical device company that develops catheter-based aspiration technology for the treatment of acute ischemic stroke.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Perfuze Comparables
Compare Perfuze with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anaconda Biomed S.L. | 92% | |
| MIVI Neuroscience | 89% | |
| RapidPulse | 89% |
For institutional investors. Book with your work email.
Perfuze Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 13, 2025 | ||||
| Series A Extension | Mar 13, 2024 | ||||
| Series A | Feb 9, 2022 | ||||
| Seed | Jan 29, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Perfuze Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A Extension, Series A |
| SV Health Investors | Series A Extension, Series A |
| Seroba Life Sciences | Series A Extension, Series A |
| Earlybird Venture Capital | Series A Extension, Series A, Seed |
| Enterprise Ireland | Seed, Series A |
| HBM Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors grew 101% MoM.
- May 20, 2026
Monthly visitors increased 32% MoM.
For institutional investors. Book with your work email.
Perfuze Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Perfuze's valuation, stock price, and market status.
Is Perfuze a public or private company?
Perfuze is a private company.
What is the current stock price of Perfuze?
Perfuze is a private company, so its shares have no public market price. Caplight tracks Perfuze's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Perfuze worth (valuation)?
Valuation information for Perfuze is not publicly available.
Can I buy Perfuze stock?
Perfuze shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Perfuze's last funding round?
Perfuze's most recent funding round was Series A Extension on March 13, 2025.
Who are the main investors in Perfuze?
Key investors in Perfuze include EQT Life Sciences, SV Health Investors, Seroba Life Sciences, Earlybird Venture Capital.
Will Perfuze IPO soon?
No public IPO plans have been announced for Perfuze.
How can I track Perfuze secondary market activity?
Caplight tracks bids, offers, and trades in Perfuze's shares on secondary markets.